A small peptide sequence for binding to multiple serotypes of adenovirus and its application

By developing small peptide sequences B11-25 for the manufacture of AAV affinity chromatography media ligands with high alkali resistance and strong broad spectrum, the alkali resistance and broad spectrum deficiency of AAV virus vector purification media in the prior art was solved. The problem of this is to achieve efficient purification of various AAV serotype viruses, reduce production costs and improve purification efficiency.

CN118530344BActive Publication Date: 2024-11-01ZHONGKE CHENXING (BEIJING) BIOMEDICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410775897.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-17
Publication Date
2024-11-01
Estimated Expiration
2044-06-17

AI Technical Summary

Technical Problem

The existing AAV virus vector purification process platform lacks the challenge of effective and amplification, especially the alkali resistance and broad spectrum of resin purification media, which leads to high production costs and low purification efficiency, and the inability to effectively purify multiple AAV serotypes. Virus.

Method used

A small peptide sequence B11-25 was developed. The 25 amino acid-length small peptide sequence screened through cloning was used to create a high alkali resistance and strong broad spectrum ligand, which can be combined with AAV2 , AAV5, AAV8 and AAV9 and other serotype viruses combine to purify AAV virus particles or vectors.

Benefits of technology

It has achieved efficient purification of various AAV serotype viruses, which have strong alkali resistance and affinity, reduce production costs, and improve purification efficiency, making the production of AAV virus vectors more economical and sustainable.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118530344B_ABST
    Figure CN118530344B_ABST
Patent Text Reader

Abstract

The present invention discloses a small peptide sequence for binding to multiple serotypes of adenovirus and its application, belonging to the field of biomedicine technology. The small peptide sequence can be used to manufacture AAV affinity chromatography medium ligand; used to bind to multiple different serotypes of adenovirus; has strong alkali resistance; has high affinity; can be used to purify AAV virus particles or AAV virus vectors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a small peptide sequence for binding to multiple serotypes of adenoviruses and an application thereof. Background Art

[0002] In recent years, cell and gene therapy drugs have developed rapidly, and a considerable number of drugs have entered the clinical trial stage. Many of them use AAV viral vectors to deliver target genes to target cells or tissues and organs. It involves the treatment of a variety of genetic diseases, such as cystic fibrosis, hemophilia, etc. In addition, they are also used to treat certain cancers and neurological diseases, such as Parkinson's disease and Huntington's disease. These trials involved patients of different age groups and achieved initial success. They showed good safety and efficacy in clinical trials. AAV viral vectors are generally considered to be a very suitable viral vector for gene therapy because they exist naturally in the human body and induce low immune responses.

[0003] Although gene therapy medical results based on adeno-associated virus have been widely reported, the application of potential therapeutic viral vectors is currently limited by manufacturing challenges, including the lack of efficient and scalable purification process platforms. Affinity chromatography has been shown to be feasible for viral vector purification, and to date, a small number of affinity fillers for certain subtypes already exist. The earliest generation of affinity chromatography was heparin affinity chromatography. The disadvantages are high binding background, animal origin (camelid-derived ligands), and limited to certain AAV serotypes (mainly AAV2). Sulfated cellulose, CellufineTM sulphated cellulose, is an alternative material to heparin resin, with similar affinity. AVB Sepharose High Performance is a star product in affinity chromatography in recent years. It can purify a variety of AAV serotypes, AAV variants and synthetic capsids. It has strong vector binding ability, acceptable concentration and high recovery rate, and has been widely used in commercial production. The affinity of AVB to AAV varies depending on the serotype. For example, AVB has a strong affinity to AAV3, but a weak affinity to AAV8 and AAV9. The reason for the difference is whether there is an AVB binding epitope with the sequence SPAKFA in the variable region of the AAV capsid. In addition to the AVB affinity column, POROS CaptureSelect Affinity resin has also received increasing attention. This resin not only has a strong AAV particle binding capacity (approximately 10 per ml of resin binds 14vg), can also be used for the purification of AAV8 and AAV9, and the recovery rate is relatively high (AAV8 ~ 80%, AAV9 ~ 73%). POROS resin has a high purification efficiency and can effectively reduce impurities in one purification; it can be used for large-scale AAV purification when combined with chromatography equipment (Mario Mietzsch et al., Characterization of AAV-Specific Affinity Ligands: Consequences for Vector Purification and Development Strategies. DOI: 10.1016 / j.omtm.2020.10.001). Interestingly, POROS resin does not bind to AAV by "specific sequence" like ABV resin. For example, AAVrh8R is more similar to AAV9, but it can only be purified with POROSAAV8 resin; while AAV-DJ is largely homologous to AAV8, AAV-DJ cannot be purified with POROS AAV8 resin. Therefore, when using the POROS system to purify a specific AAV, it must be tested. POROS Capture Select TM The system has also developed AAVX affinity resin. POROS AAVX can be used for a wide range of serotypes, including AAV1-8, AAVrh10, and some other synthetic serotypes (Jihad El Andari and Dirk Grimm, Production, Processing, and Characterization of Synthetic AAV Gene Therapy Vectors. DOI: 10.1002 / biot.202000025). However, a big problem with this type of affinity resin is that it is not alkali-resistant, so the affinity chromatography column of the AAV viral vector becomes "disposable", which greatly increases the production cost of the AAV viral vector.

[0004] Repligen has developed -AAV series affinity fillers can achieve one-step purification of AAV-2, AAV-8 or AAV-9 viral vectors, and can be regenerated by online alkaline cleaning to improve process economy. 50μm cross-linked agarose-based balls ensure compatibility with standard bioprocess chromatography columns and flow rates (3bar@300cm / hr). It is understood that the ligands used in Repligen's AVIPure series affinity fillers are modified small peptide ligands. The only drawback is that Repligen's AVIPure series affinity fillers can only purify a certain serotype and have poor broad-spectrum properties. The reason for this situation is that the small peptides do not have a broad-spectrum property at the position where they bind to AAV.

[0005] In order to minimize the cost of gene therapy based on AAV viral vectors, the ability to purify multiple serotypes of viruses using one resin is crucial, and it is best to have a certain degree of alkaline resistance (tolerance to cleaning with NaOH solution) so that such chromatography media can be reused to further reduce costs. Therefore, screening and developing a small peptide that can bind to multiple serotypes of AAV viral vectors is crucial to achieving the above goals. Summary of the invention

[0006] Biological products (pharmaceuticals) such as AAV viral vectors for gene therapy are expensive, and their quality is subject to strict review and supervision to ensure their effectiveness and safety. Therefore, low-cost, high-efficiency purification methods are particularly important for the life cycle of biological products (pharmaceuticals). The purpose of the present invention is to provide a small peptide sequence for binding to multiple serotypes of adenoviruses, which can be used to manufacture AAV affinity chromatography medium ligands; used to bind to multiple different serotypes of adenoviruses; has strong alkali resistance; has high affinity; can be used to purify AAV virus particles or AAV virus vectors.

[0007] The present invention is achieved through the following technical solutions:

[0008] A small peptide sequence for binding to multiple serotypes of adenoviruses, the amino acid sequence of the small peptide sequence is shown as SEQ ID NO.1.

[0009] Preferably, the small peptide sequence is a small peptide sequence of 25 amino acids in length screened out from clone B11.

[0010] Preferably, the serotype adenovirus is any one of AAV2, AAV5, AAV8 and AAV9.

[0011] The invention discloses an application of a small peptide sequence for binding to multiple serotypes of adenoviruses in preparing AAV affinity chromatography medium ligand.

[0012] An affinity chromatography medium ligand comprises the small peptide sequence.

[0013] The invention discloses an application of an affinity chromatography medium ligand in preparing purified AAV virus particles or AAV virus vector products.

[0014] An alkaline-resistant affinity chromatography medium ligand, comprising the small peptide sequence for binding to multiple serotypes of adenovirus or the affinity chromatography medium ligand as claimed in claim 5.

[0015] Preferably, the affinity chromatography medium ligand is able to resist the action of 0.15N sodium hydroxide solution.

[0016] An affinity chromatography preparation comprising the affinity chromatography medium ligand or the alkaline-resistant affinity chromatography medium ligand as claimed in claim 7.

[0017] Compared with the prior art, the present invention has at least the following technical effects:

[0018] The present invention provides a small peptide sequence for binding to multiple serotypes of adenoviruses. The small peptide sequence can be used to manufacture AAV affinity chromatography medium ligands; is used to bind to multiple different serotypes of adenoviruses; has strong alkali resistance; has high affinity; and can be used to purify AAV virus particles or AAV virus vectors. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is a schematic diagram of the conserved sequences of VP1, VP2, and VP3 proteins on the surface of AAV;

[0020] Figure 2 This is a schematic diagram of the expression results of VP3 immunogens of 10 different serotypes of AAV viruses, from AAV-1 to AAV-10;

[0021] Figure 3 A schematic diagram of the polypeptide structure of the small peptide sequence of this application;

[0022] Figure 4 It is the AAV VP3 capsid protein, of which the dark orange is chain A;

[0023] Figure 5 Schematic diagram of the interaction between VP3 and B11-25. DETAILED DESCRIPTION

[0024] The embodiments of the present invention will be described in detail below in conjunction with examples. However, those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. The specific conditions not specified in the examples are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.

[0025] A technical solution of a specific implementation of the present invention is:

[0026] Theoretically, there are conserved surface sequences among AAV viral vectors of different serotypes, which makes it possible to screen small peptides with broad-spectrum binding activity.

[0027] like Figure 1 Shown is a schematic diagram of the conserved sequences of VP1, VP2, and VP3 proteins on the surface of AAV.

[0028] In the figure, the AAV surface VP3 protein contains conservative sequences such as GADGVGX1X2SGX3WHCDS, STRTWX4LPX5YNNH, STPWGYFDFNRFH, SPRDWQRLINN, FNIQVKEVT, CLEYFPSX6MLRTGNNF, etc. In theory, these regions can become broad-spectrum epitopes recognized by small peptides.

[0029] Among them, X1=N or S; X2=A or S; X3=N or D; X4=A or V; X5=T or S; X6=Q or K.

[0030] 1. Obtaining immunogens

[0031] The VP3 protein genes of 10 different serotypes of AAV viruses, such as AAV-1 to AAV-10, were synthesized with a polyhistidine tag (6x His tag) at the C-terminus and cloned into the NdeI-XhoI region of pET-30a(+). The genes were then transformed into the E. coli expression strain BL21(DE3) for expression.

[0032] like Figure 2 Shown is a schematic diagram of the expression results of VP3 immunogens of 10 different serotypes of AAV viruses, from AAV-1 to AAV-10.

[0033] Figure 2 Ten VP3 immunogens were prepared, but some of them were fragmented.

[0034] The AAV-1VP3 amino acid sequence is shown in SEQ ID NO.2;

[0035] The AAV-2VP3 amino acid sequence is shown in SEQ ID NO.3;

[0036] The AAV-3VP3 amino acid sequence is shown in SEQ ID NO.4;

[0037] The AAV-4VP3 amino acid sequence is shown in SEQ ID NO.5;

[0038] The AAV-5VP3 amino acid sequence is shown in SEQ ID NO.6;

[0039] The AAV-6VP3 amino acid sequence is shown in SEQ ID NO.7;

[0040] The AAV-7VP3 amino acid sequence is shown in SEQ ID NO.8;

[0041] The AAV-8VP3 amino acid sequence is shown in SEQ ID NO.9;

[0042] The AAV-9VP3 amino acid sequence is shown in SEQ ID NO.10;

[0043] The AAV-10VP3 amino acid sequence is shown in SEQ ID NO.11.

[0044] In order to improve the immune effect, purified AAV-2, AAV-5, AAV-8, and AAV-9 serotype virus vectors were purchased from Shanghai Heyuan Biotechnology and used as virus particle-like immunogens in subsequent alpaca immunization. The information of the four virus vectors is shown in Table 1 below.

[0045] Table 1

[0046]

[0047]

[0048] 2. Immunize alpacas with immunogen to obtain immune serum

[0049] ①Immunization plan:

[0050] Take 50 μL of AAV-9 and dilute to 10 mL, then divide into 5 tubes, 2 mL / tube; take 50 μL each of AAV-2 / 5 / 8 and dilute to 2 mL respectively.

[0051] First shot: AAV-9 2mL

[0052] Second shot: AAV-9 2mL

[0053] The third injection: add 25 μL of AAV-2 / 5 / 9 to 2 mL of AAV-9

[0054] Fourth injection: add 25 μL each of AAV2-2 / 5 / 9 to 2 mL of AAV-9

[0055] Fifth injection: 200 μg of VP3 protein of AAV-2 / 5 / 8 / 9

[0056] ②Immunization progress chart

[0057] Table 2

[0058] content Days (days) Serum collection amount / immunization dose Negative serum collection 0 2 mL of serum was collected before immunization Primary immunization 1 First shot, intramuscular injection Secondary Immunization 14 Second shot, intramuscular injection Three immunizations 28 The third shot, intramuscular injection Four immunizations 42 Fourth shot, intramuscular injection Serum collection and ELISA testing 49 Collect 2mL of serum for titer test Five immunizations 56 Fifth injection, intramuscular injection Serum collection and ELISA testing 63 Collect 2mL of serum for titer test

[0059] ③Construct immune library: Take B lymphocytes from alpaca blood, extract RNA from them and transcribe them into cDNA. Construct alpaca antibody gene library. Use the library and VP3 protein for alpaca nanoantibody screening (ELISA method).

[0060] ④ Obtain the nanoantibody sequence by sequencing, and synthesize the CDR3 amino acid sequence therein.

[0061]

[0062]

[0063]

[0064] The above sequence B11-25 is the small peptide sequence protected by the technical solution of the present application. B11-25 is a code named by the inventor himself, which refers to a small peptide with a length of 25 amino acids screened out from clone B11.

[0065] In the content of this application document, the small peptide sequences protected by the technical scheme of this application are all represented by B11-25.

[0066] 3. Use molecular docking to determine the theoretical binding site between the small peptide and VP3

[0067] The B11-25 peptide is the CDR3 region of the VHH of the anti-AAV VP3 protein. Based on its sequence, the peptide structure was constructed using AlphaFold2 (e.g. Figure 3 shown).

[0068] The crystal structure 8FQ4 is a capsid protein assembled by the interaction of 60 AAV VP3s. Figure 4 The B11-25 peptide was docked (using Rosetta software) to predict their interaction.

[0069] Docking revealed that B11-25 interacted with Asp532, Lys491, Thr492, Tyr705, Asp556, Asn557, Glu546, and Gly719 residues of VP3 protein.

[0070] Table 3

[0071]

[0072] Docking diagram Figure 5 Shown is the interaction between VP3 and B11-25.

[0073] 4. Affinity of small peptides and AAV viral vectors

[0074] Octet Fortebio K2 and AAVX-biosensor were used to detect the affinity of small peptides. Dilution buffer: PSBT (1×PBS + 0.02% Tween 20)

[0075] Fixed objects: AAV2, AAV5, AAV8, AAV9 (4×10 11vg / ml); Analyte: B11-25 (20 μM). The test results are as follows:

[0076] Table 4

[0077] Fixtures KD(M) AAV2 (20 μM) 1.52E-08 AAV5 (20 μM) 2.57E-08 AAV8 (20 μM) 3.07E-07 AAV9 (20 μM) 2.36E-07

[0078] The results in the above table show that the B11-25 peptide has certain binding activity with AAV-2, AAV-5, AAV-8, and AAV-9.

[0079] 5. Alkali resistance of small peptides

[0080] The peptide was placed in 0.15N NaOH, 0.5N NaOH and 1N NaOH aqueous solutions for 30 minutes each, then the alkali solution was dialyzed away and the affinity was tested again.

[0081] Table 5

[0082] B11-25 small peptide 0 0.15N NaOH 0.5N NaOH 1N NaOH The percentage of affinity decrease after 30 minutes of action 0 5% 15% 52%

[0083] The above results show that the small peptide can resist the action of 0.15N NaOH and its affinity decreases to varying degrees in high concentration alkali solution.

[0084] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the protection scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A small peptide for binding to multiple serotypes of adenovirus, characterized in that: The amino acid sequence of the small peptide is shown in SEQ ID NO.

1.

2. A use of the small peptide for binding to multiple serotypes of adenoviruses as claimed in claim 1 in the preparation of AAV affinity chromatography medium ligand, characterized in that: The AAV is any one of AAV2, AAV5, AAV8 and AAV9.

3. An affinity chromatography medium ligand, characterized in that: Comprising the small peptide as claimed in claim 1.

4. A use of the affinity chromatography medium ligand as claimed in claim 3 in the preparation of purified AAV virus particles or AAV virus vector products, characterized in that: The AAV is any one of AAV2, AAV5, AAV8 and AAV9.

5. An alkaline-resistant affinity chromatography medium ligand, characterized in that: It comprises the small peptide for binding to multiple serotypes of adenovirus as claimed in claim 1 or the affinity chromatography medium ligand as claimed in claim 3.

6. The alkaline-resistant affinity chromatography medium ligand according to claim 5, characterized in that: The affinity chromatography medium ligand can resist the action of 0.15N sodium hydroxide solution.

7. An affinity chromatography preparation, characterized in that It comprises the affinity chromatography medium ligand as claimed in claim 3 or the alkaline-resistant affinity chromatography medium ligand as claimed in claim 5.